Last updated on September 2014

Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer


Brief description of study

The objective of this study is to assess efficacy and safety of radium-223 dichloride in subjects with human epidermal growth factor receptor 2 negative (HER2 negative) hormone receptor positive breast cancer with bone metastases treated with hormonal treatment background therapy.

Clinical Study Identifier: NCT02258464

Find a site near you

Start Over

Bayer Clinical Trials Contact

New Territories, Hong Kong
2.0miles
  Connect »

Bayer Clinical Trials Contact

Shatin, Hong Kong
5.77miles
  Connect »

Bayer Clinical Trials Contact

Kowloon, Hong Kong
7.0miles
  Connect »